Ultragenyx Pharmaceutical (RARE) Retained Earnings (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Retained Earnings for 13 consecutive years, with -$4.5 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, Retained Earnings fell 207.57% year-over-year to -$4.5 billion; the TTM figure through Dec 2025 stood at -$4.5 billion (down 207.57% YoY), while the FY2025 annual figure was -$4.5 billion, down 207.57% from the prior year.
• Retained Earnings retreated to -$4.5 billion in Q4 2025 per RARE's latest filing, from $4.4 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $4.4 billion in Q3 2025 and bottomed at -$4.5 billion in Q4 2025.
• Historically, Retained Earnings has averaged $597.4 million across 5 years, with a median of -$718000.0 in 2024.
• Annual changes were most pronounced in 2023 — Retained Earnings tumbled 44834.3% — and 2025, when it soared 399582.47%.
• Ultragenyx Pharmaceutical's Retained Earnings stood at -$2.1 billion in 2021, then plunged by 34.12% to -$2.8 billion in 2022, then surged by 231.69% to $3.7 billion in 2023, then increased by 15.04% to $4.2 billion in 2024, then tumbled by 207.57% to -$4.5 billion in 2025.
• Business Quant data shows RARE's Retained Earnings at -$4.5 billion in Q4 2025, $4.4 billion in Q3 2025, and $4.4 billion in Q2 2025.